EORTC/LinkedIn
Apr 17, 2025, 07:21
A joint European Medicines Agency–EORTC workshop
EORTC – European Organisation for Research and Treatment of Cancer posted on LinkedIn:
“New Publication at The Lancet Oncology.
A joint European Medicines Agency–EORTC workshop (Feb 2024) brought together patients, regulators, academia, HTA bodies, and industry to discuss the use of patient-reported outcomes (PROs) in anti-cancer treatment evaluation.
- PROs contribute to benefit-risk assessment.
- Considering what matters most to patients when selecting PROs is crucial.
- Need for robust and consistent methodologies.
As the clinical trial landscape evolves, so must our strategies for measuring patients’ quality of life and for ensuring the patient voice is incorporated in the decision-making process.
Read more in our press release about this new article by Madeline Pe, Caroline Voltz-Girolt et al.“
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 20:22
Apr 18, 2025, 20:12
Apr 18, 2025, 20:03
Apr 18, 2025, 19:54
Apr 18, 2025, 19:49
Apr 18, 2025, 19:44
Apr 18, 2025, 19:26